#1

• Antalis, C.J., et al., “Omega-3 Fatty Acid Status in Attention-Deficit/ Hyperactivity Disorder,” Prostaglandins Leukot Essent Fatty Acids, 2006. 75(4-5): p. 299-308.
• Belanger, et. al., “Omega-3 Fatty Acid Treatment of Children with Attention-Deficit Hyperactivity Disorder: A Randomized, Double-Blind, Placebo-Controlled Study,” Pediatric Child Health, 2009; 14(2): p. 89-98.
• Bloch, et. al., “Omega-3 Fatty Acid Supplementation for the Treatment of Children with Attention-Deficit/Hyperactivity Disorder Symptomology: Systematic Review and Meta-Analysis,” J Am Acad Child Adolesc Psychiatry, October 2011; 50(10) p. 991-1000.
• Bos, et. al., “Reduced Symptoms of Inattention after Dietary Omega-3 Fatty Acid Supplementation in Boys with and without Attention Deficit/Hyperactivity Disorder,” Neuropsychopharmacology, (2015) 40, p. 2298-2306.
• Burgess, J.R., et al., “Long-Chain Polyunsaturated Fatty Acids in Children with Attention-Deficit Hyperactivity Disorder,” Am J Clin Nutr, 2000. 71(1 Suppl): p. 327S-30S.
• Gustafsson, et. al., “EPA Supplementation Improves Teacher-Rated Behavior and Oppositional Symptoms in Children with ADHD.” Acta Paediatr 2010; 99: 1540–1549.
• Johnson, et. al., “Omega-3/Omega-6 Fatty Acids for Attention Deficit Disorder: A Randomized Placebo-Controlled Trial in Children and Adolescents,” Journal of Attention Disorders, 2008, p. 1-8.
• Kidd, et al., “Attention-deficit/Hyperactivity Disorder (ADHD) in Children: Rationale for its Integrative Management, Alternative Medicine Review, Vol. 5, No. 5, 2000: p. 402-428.
• Konig, et al., “Critical Appraisal of Omega-3 Fatty Acids in Attention-Deficit/Hyperactivity Disorder Treatment,” Neuropsychiatric Disease and Treatment, 2016: 12, p. 1869-1882
  Milte, et. al., “Eicosapentaenoic and Docosahexaenoic Acids, Cognition, and Behavior in Children with Attention Deficit/Hyperactivity Disorder: A Randomized Controlled Trial,” Nutrition, (2012) 28; p. 670-677. Richardson, et. al., “A Randomized Double-Blind, Placebo-Controlled Study of the Effects of Supplementation with Highly Unsaturated Fatty Acids on ADHD-Related Symptoms in Children with Specific Learning Difficulties,” Progress in Neuro-Psychopharmacology Biological Psychiatry, 26 (2002) p. 233-239.
• Sinn, et al. “Effect of Supplementation with Polyunsaturated Fatty Acids and Micronutrients on Learning and Behavior Problems Associated with Child ADHD,” Journal of Developmental and Behavioral Problems, Vol. 28, No. 2, Jan. 2007, p. 82-91.
• Richardson, et. al., “A Randomized Double-Blind, Placebo-Controlled Study of the Effects of Supplementation with Highly Unsaturated Fatty Acids on ADHD-Related Symptoms in Children with Specific Learning Difficulties,” Progress in Neuro-Psychopharmacology Biological Psychiatry, 26 (2002) p. 233-239.
  Richardson, et. al., “A Randomized Controlled Trial of Dietary Supplementation with Fatty Acids in Children with Developmental Coordination Disorder,” Pediatrics, 115(5): 1360-1366.
• Richardson, et. al., “The Potential Role of Fatty Acids in Attention-Deficit / Hyperactivity Disorder, “Prostaglandins, Leukotrienes, and Essential Fatty Acids, Vol. 63, Issue 12, July 2000.
• Richardson, et. al., “Omega-3 Fatty Acids in ADHD and Related Neurodevelopmental Disorders,” International Review of Psychiatry, April 2006; 18 (2): p. 155-172.

#2

• Gokcen, et. al., “Methylenetetrahydrofolate Reductase Gene Polymorphisms in Children with Attention Deficit Disorder,” Int. J. Med. Sci., 2011;8 p. 523-528.
• Goksugur, et al., “Vitamin D Status in Children with Attention-Deficit/Hyperactivity Disorder,” Pediatrics International, August 2014; 56(4): p. 515-19.
• Kidd, et al., “Attention-deficit/Hyperactivity Disorder (ADHD) in Children: Rationale for its Integrative Management, Alternative Medicine Review, Vol. 5, No. 5, 2000: p. 402-428.
• Patrick, et. al., “Vitamin D and the Omega-3 Fatty Acids Control Serotonin Synthesis and Action, part 2: Relevance for ADHD, Bipolar Disorder, Schizophrenia, and Impulsive Behavior,” The FASEB Journal, February 2017, Vol. 29, No. 6, p: 2207-2222.
• Saha, et al. “A Pilot Study on the Contribution of Folate Gene Variants in the Cognitive Function of ADHD Probands,” Neurochem Res, (2014) 39: p. 2058-2067.
• Sharif, et al., “The Relationship Between Serum Vitamin D Level and Attention-Deficit/Hyperactivity Disorder,” Iranian Journal of Child Neurology, Fall 2015; 9(4): p. 48-53.
• Shaw, et al., “A Possible Biological Mechanism for the B Vitamins Altering Behavior in Attention-Deficit/Hyperactivity Disorder,” Pharm Med, 2010; 24 (5): p. 289-294.

#3

• Akhondzadeh, et al., “Zinc sulfate as an adjunct to methylphenidate for the treatment of attention deficit hyperactivity disorder in children: A double blind and randomized trial,” BMC Psychiatry, 2004, 4:9.
• Baza, et at., “Magnesium Supplementation in Children with Attention-Deficit/Hyperactivity Disorder,” The Egyptian Journal of Medical Human Genetics, (2016) 17, p. 63-70.
• Ghanizadeh, et al., “A systemic Review of Magnesium Therapy for Treating Attention Deficit Hyperactivity Disorder,” Archives of Iranian Medicine, July 2013, 16(7): p. 412-17.
• Gordon, et al., “Clinically Significant Symptom Reduction in Children with Attention-Deficit/Hyperactivity Disorder Treated with Micronutrients: An Open-Label Reversal Design Study,” J Child Adolesc Psychopharmacol. 2015 Dec 1; 25(10): p. 783–798.
• Konofal, et al, “Iron deficiency in children with attention-deficit/hyperactivity disorder,” Arch Pediatr Adolesc Med, 2004; 158: 1113-5.
• Kozielec, et al., “Assessment of Magnesium Levels in Children with Attention-Deficit/Hyperactivity Disorder (ADHD),” Magnesium Research, June 1997; 10(2): p. 143-148.
• Lakhan, et al. “Nutritional Therapies for Mental Disorders” Nutritional Journal, Jan. 2008; 7:2.
• Mousain-Bosc, et al., “Improvement of Neurobehavioral Disorders in Children Supplemented with Magnesium-Vitamin B6 in Attention Deficit Hyperactivity Disorders,” Magnesium Research, 2006; 19(1): p. 46-52.
• Rucklidge, et. al., “Broad-Spectrum Micronutrient Treatment for Attention-Deficit/Hyperactivity Disorder: Rationale and Evidence to Date,” CNS drugs 28 (2014): 775-785.
• Slutsky, et al., “Enhancement of Learning Memory by Elevating Brain Magnesium,” Nueron, January 2010: 65, p. 165-177.
• Toren, et al. “Zinc deficiency in attention-deficit hyperactivity disorder,” Biological Psychiatry, Vol. 40, Issue 12, 1308 – 1310.
• Villagomez, et. al., “Iron, Magnesium, Vitamin D, and Zinc Deficiencies in Children Presenting with Symptoms of Attention-Deficit Hyperactivity Disorder,” Children, 2014, 1: 261-279.
• Youdim MB, Yehuda S. The neurochemical basis of cognitive deficits induced by brain iron deficiency: involvement of dopamine–opiate system. Cell. Mol. Biol. (Noisy-le-Grand) 46(3), 491–500 (2000).

#4

• Antalis, C.J., et al., “Omega-3 Fatty Acid Status in Attention-Deficit/ Hyperactivity Disorder,” Prostaglandins Leukot Essent Fatty Acids, 2006. 75(4-5): p. 299-308.
• Belanger, et. al., “Omega-3 Fatty Acid Treatment of Children with Attention-Deficit Hyperactivity Disorder: A Randomized, Double-Blind, Placebo-Controlled Study,” Pediatric Child Health, 2009; 14(2): p. 89-98.
• Bloch, et. al., “Omega-3 Fatty Acid Supplementation for the Treatment of Children with Attention-Deficit/Hyperactivity Disorder Symptomology: Systematic Review and Meta-Analysis,” J Am Acad Child Adolesc Psychiatry, October 2011; 50(10) p. 991-1000.
• Bos, et. al., “Reduced Symptoms of Inattention after Dietary Omega-3 Fatty Acid Supplementation in Boys with and without Attention Deficit/Hyperactivity Disorder,” Neuropsychopharmacology, (2015) 40, p. 2298-2306.
• Burgess, J.R., et al., “Long-Chain Polyunsaturated Fatty Acids in Children with Attention-Deficit Hyperactivity Disorder,” Am J Clin Nutr, 2000. 71(1 Suppl): p. 327S-30S.
• Gustafsson, et. al., “EPA Supplementation Improves Teacher-Rated Behavior and Oppositional Symptoms in Children with ADHD.” Acta Paediatr 2010; 99: 1540–1549.
• Johnson, et. al., “Omega-3/Omega-6 Fatty Acids for Attention Deficit Disorder: A Randomized Placebo-Controlled Trial in Children and Adolescents,” Journal of Attention Disorders, 2008, p. 1-8.
• Kidd, et al., “Attention-deficit/Hyperactivity Disorder (ADHD) in Children: Rationale for its Integrative Management, Alternative Medicine Review, Vol. 5, No. 5, 2000: p. 402-428.
• Konig, et al., “Critical Appraisal of Omega-3 Fatty Acids in Attention-Deficit/Hyperactivity Disorder Treatment,” Neuropsychiatric Disease and Treatment, 2016: 12, p. 1869-1882
• Milte, et. al., “Eicosapentaenoic and Docosahexaenoic Acids, Cognition, and Behavior in Children with Attention Deficit/Hyperactivity Disorder: A Randomized Controlled Trial,” Nutrition, (2012) 28; p. 670-677.
• Richardson, et. al., “A Randomized Double-Blind, Placebo-Controlled Study of the Effects of Supplementation with Highly Unsaturated Fatty Acids on ADHD-Related Symptoms in Children with Specific Learning Difficulties,” Progress in Neuro-Psychopharmacology Biological Psychiatry, 26 (2002) p. 233-239.
• Sinn, et al. “Effect of Supplementation with Polyunsaturated Fatty Acids and Micronutrients on Learning and Behavior Problems Associated with Child ADHD,” Journal of Developmental and Behavioral Problems, Vol. 28, No. 2, Jan. 2007, p. 82-91.
• Richardson, et. al., “A Randomized Double-Blind, Placebo-Controlled Study of the Effects of Supplementation with Highly Unsaturated Fatty Acids on ADHD-Related Symptoms in Children with Specific Learning Difficulties,” Progress in Neuro-Psychopharmacology Biological Psychiatry, 26 (2002) p. 233-239.
• Richardson, et. al., “A Randomized Controlled Trial of Dietary Supplementation with Fatty Acids in Children with Developmental Coordination Disorder,” Pediatrics, 115(5): 1360-1366.
• Richardson, et. al., “The Potential Role of Fatty Acids in Attention-Deficit / Hyperactivity Disorder, “Prostaglandins, Leukotrienes, and Essential Fatty Acids, Vol. 63, Issue 12, July 2000.
• Richardson, et. al., “Omega-3 Fatty Acids in ADHD and Related Neurodevelopmental Disorders,” International Review of Psychiatry, April 2006; 18 (2): p. 155-172.

#5

• Bekarglu, et al., “Relation between serum free fatty acids and zinc, and attention deficit hyperactivity disorder: a research note.” J Child Psychol Psychiat, 1996, 37: 225-227.
  
• Gordon, et al., “Clinically Significant Symptom Reduction in Children with Attention-Deficit/Hyperactivity Disorder Treated with Micronutrients: An Open-Label Reversal Design Study,” J Child Adolesc Psychopharmacol. 2015 Dec 1; 25(10): p. 783–798.
  
• Lakhan, et al. “Nutritional Therapies for Mental Disorders” Nutritional Journal, Jan. 2008; 7:2.
  
• Patrick, et. al., “Vitamin D and the Omega-3 Fatty Acids Control Serotonin Synthesis and Action, part 2: Relevance for ADHD, Bipolar Disorder, Schizophrenia, and Impulsive Behavior,” The FASEB Journal, February 2017, Vol. 29, No. 6, p: 2207-2222.
  
• Saha, et al. “A Pilot Study on the Contribution of Folate Gene Variants in the Cognitive Function of ADHD Probands,” Neurochem Res, (2014) 39: p. 2058-2067.
  
• Sharif, et al., “The Relationship Between Serum Vitamin D Level and Attention-Deficit/Hyperactivity Disorder,” Iranian Journal of Child Neurology, Fall 2015; 9(4): p. 48-53.
  
• Shaw, et al., “A Possible Biological Mechanism for the B Vitamins Altering Behavior in Attention-Deficit/Hyperactivity Disorder,” Pharm Med, 2010; 24 (5): p. 289-294.
  
• Rucklidge, et. al., “Broad-Spectrum Micronutrient Treatment for Attention-Deficit/Hyperactivity Disorder: Rationale and Evidence to Date,” CNS drugs 28 (2014): 775-785.

#6

• Richardson, et. al., “A Randomized Double-Blind, Placebo-Controlled Study of the Effects of Supplementation with Highly Unsaturated Fatty Acids on ADHD-Related Symptoms in Children with Specific Learning Difficulties,” Progress in Neuro-Psychopharmacology Biological Psychiatry, 26 (2002) p. 233-239.
  
• Sinn, et al. “Effect of Supplementation with Polyunsaturated Fatty Acids and Micronutrients on Learning and Behavior Problems Associated with Child ADHD,” Journal of Developmental and Behavioral Problems, Vol. 28, No. 2, Jan. 2007, p. 82-91.
  
• Antalis, C.J., et al., “Omega-3 Fatty Acid Status in Attention-Deficit/ Hyperactivity Disorder,” Prostaglandins Leukot Essent Fatty Acids, 2006. 75(4-5): p. 299-308.
  
• Belanger, et. al., “Omega-3 Fatty Acid Treatment of Children with Attention-Deficit Hyperactivity Disorder: A Randomized, Double-Blind, Placebo-Controlled Study,” Pediatric Child Health, 2009; 14(2): p. 89-98.
  
• Bloch, et. al., “Omega-3 Fatty Acid Supplementation for the Treatment of Children with Attention-Deficit/Hyperactivity Disorder Symptomology: Systematic Review and Meta-Analysis,” J Am Acad Child Adolesc Psychiatry, October 2011; 50(10) p. 991-1000.
  
• Bos, et. al., “Reduced Symptoms of Inattention after Dietary Omega-3 Fatty Acid Supplementation in Boys with and without Attention Deficit/Hyperactivity Disorder,” Neuropsychopharmacology, (2015) 40, p. 2298-2306.
  
• Burgess, J.R., et al., “Long-Chain Polyunsaturated Fatty Acids in Children with Attention-Deficit Hyperactivity Disorder,” Am J Clin Nutr, 2000. 71(1 Suppl): p. 327S-30S.
  
• Gustafsson, et. al., “EPA Supplementation Improves Teacher-Rated Behavior and Oppositional Symptoms in Children with ADHD.” Acta Paediatr 2010; 99: 1540–1549.
  
• Johnson, et. al., “Omega-3/Omega-6 Fatty Acids for Attention Deficit Disorder: A Randomized Placebo-Controlled Trial in Children and Adolescents,” Journal of Attention Disorders, 2008, p. 1-8.
  
• Kidd, et al., “Attention-deficit/Hyperactivity Disorder (ADHD) in Children: Rationale for its Integrative Management, Alternative Medicine Review, Vol. 5, No. 5, 2000: p. 402-428.
  
• Konig, et al., “Critical Appraisal of Omega-3 Fatty Acids in Attention-Deficit/Hyperactivity Disorder Treatment,” Neuropsychiatric Disease and Treatment, 2016: 12, p. 1869-1882.
  
• Milte, et. al., “Eicosapentaenoic and Docosahexaenoic Acids, Cognition, and Behavior in Children with Attention Deficit/Hyperactivity Disorder: A Randomized Controlled Trial,” Nutrition, (2012) 28; p. 670-677.
  
• Richardson, et. al., “A Randomized Double-Blind, Placebo-Controlled Study of the Effects of Supplementation with Highly Unsaturated Fatty Acids on ADHD-Related Symptoms in Children with Specific Learning Difficulties,” Progress in Neuro-Psychopharmacology Biological Psychiatry, 26 (2002) p. 233-239.
  
• Richardson, et. al., “A Randomized Controlled Trial of Dietary Supplementation with Fatty Acids in Children with Developmental Coordination Disorder,” Pediatrics, 115(5): 1360-1366.
  
• Richardson, et. al., “Omega-3 Fatty Acids in ADHD and Related Neurodevelopmental Disorders,” International Review of Psychiatry, April 2006; 18 (2): p. 155-172.
  
• Richardson, et. al., “The Potential Role of Fatty Acids in Attention-Deficit / Hyperactivity Disorder, “Prostaglandins, Leukotrienes, and Essential Fatty Acids, Vol. 63, Issue 12, July 2000.

#7

• Akhondzadeh, et al., “Zinc sulfate as an adjunct to methylphenidate for the treatment of attention deficit hyperactivity disorder in children: A double blind and randomized trial,” BMC Psychiatry, 2004, 4:9.
  
• Baza, et at., “Magnesium Supplementation in Children with Attention-Deficit/Hyperactivity Disorder,” The Egyptian Journal of Medical Human Genetics, (2016) 17, p. 63-70.
  
• Ghanizadeh, et al., “A systemic Review of Magnesium Therapy for Treating Attention Deficit Hyperactivity Disorder,” Archives of Iranian Medicine, July 2013, 16(7): p. 412-17.
  
• Gordon, et al., “Clinically Significant Symptom Reduction in Children with Attention-Deficit/Hyperactivity Disorder Treated with Micronutrients: An Open-Label Reversal Design Study,” J Child Adolesc Psychopharmacol. 2015 Dec 1; 25(10): p. 783–798.
  
• Konofal, et al, “Iron deficiency in children with attention-deficit/hyperactivity disorder,” Arch Pediatr Adolesc Med, 2004; 158: 1113-5.
  
• Kozielec, et al., “Assessment of Magnesium Levels in Children with Attention-Deficit/Hyperactivity Disorder (ADHD),” Magnesium Research, June 1997; 10(2): p. 143-148.
  
• Lakhan, et al. “Nutritional Therapies for Mental Disorders” Nutritional Journal, Jan. 2008; 7:2.
  
• Mousain-Bosc, et al., “Improvement of Neurobehavioral Disorders in Children Supplemented with Magnesium-Vitamin B6 in Attention Deficit Hyperactivity Disorders,” Magnesium Research, 2006; 19(1): p. 46-52.
  
• Rucklidge, et. al., “Broad-Spectrum Micronutrient Treatment for Attention-Deficit/Hyperactivity Disorder: Rationale and Evidence to Date,” CNS drugs 28 (2014): 775-785.
  
• Slutsky, et al., “Enhancement of Learning Memory by Elevating Brain Magnesium,” Nueron, January 2010: 65, p. 165-177.
  
• Toren, et al. “Zinc deficiency in attention-deficit hyperactivity disorder,” Biological Psychiatry, Vol. 40, Issue 12, 1308 – 1310.
  
• Villagomez, et. al., “Iron, Magnesium, Vitamin D, and Zinc Deficiencies in Children Presenting with Symptoms of Attention-Deficit Hyperactivity Disorder,” Children, 2014, 1: 261-279.
  
• Youdim MB, Yehuda S. The neurochemical basis of cognitive deficits induced by brain iron deficiency: involvement of dopamine–opiate system. Cell. Mol. Biol. (Noisy-le-Grand) 46(3), 491–500 (2000).
  

#8

• Gordon, et al., “Clinically Significant Symptom Reduction in Children with Attention-Deficit/Hyperactivity Disorder Treated with Micronutrients: An Open-Label Reversal Design Study,” J Child Adolesc Psychopharmacol. 2015 Dec 1; 25(10): p. 783–798.
  
• Lakhan, et al. “Nutritional Therapies for Mental Disorders” Nutritional Journal, Jan. 2008; 7:2.
  
• Rucklidge, et. al., “Broad-Spectrum Micronutrient Treatment for Attention-Deficit/Hyperactivity Disorder: Rationale and Evidence to Date,” CNS drugs 28 (2014): 775-785.
  
• Rucklidge, et. al., “Vitamin-Mineral Treatment Improves Aggression and Emotional Regulation in Children with ADHD: A Fully Blinded, Randomized, Placebo-Controlled Trial,” Journal of Child Psychology and Psychiatry, 2017: p. 1-15
  

#9

• Akhondzadeh, et al., “Zinc sulfate as an adjunct to methylphenidate for the treatment of attention deficit hyperactivity disorder in children: A double blind and randomized trial,” BMC Psychiatry, 2004, 4:9.
  
• Baza, et at., “Magnesium Supplementation in Children with Attention-Deficit/Hyperactivity Disorder,” The Egyptian Journal of Medical Human Genetics, (2016) 17, p. 63-70.
  
• Ghanizadeh, et al., “A systemic Review of Magnesium Therapy for Treating Attention Deficit Hyperactivity Disorder,” Archives of Iranian Medicine, July 2013, 16(7): p. 412-17.
  
• Gordon, et al., “Clinically Significant Symptom Reduction in Children with Attention-Deficit/Hyperactivity Disorder Treated with Micronutrients: An Open-Label Reversal Design Study,” J Child Adolesc Psychopharmacol. 2015 Dec 1; 25(10): p. 783–798.
  
• Konofal, et al, “Iron deficiency in children with attention-deficit/hyperactivity disorder,” Arch Pediatr Adolesc Med, 2004; 158: 1113-5.
  
• Kozielec, et al., “Assessment of Magnesium Levels in Children with Attention-Deficit/Hyperactivity Disorder (ADHD),” Magnesium Research, June 1997; 10(2): p. 143-148.
  
• Lakhan, et al. “Nutritional Therapies for Mental Disorders” Nutritional Journal, Jan. 2008; 7:2.
  
• Mousain-Bosc, et al., “Improvement of Neurobehavioral Disorders in Children Supplemented with Magnesium-Vitamin B6 in Attention Deficit Hyperactivity Disorders,” Magnesium Research, 2006; 19(1): p. 46-52.
  
• Rucklidge, et. al., “Broad-Spectrum Micronutrient Treatment for Attention-Deficit/Hyperactivity Disorder: Rationale and Evidence to Date,” CNS drugs 28 (2014): 775-785.
  
• Slutsky, et al., “Enhancement of Learning Memory by Elevating Brain Magnesium,” Nueron, January 2010: 65, p. 165-177.
  
• Toren, et al. “Zinc deficiency in attention-deficit hyperactivity disorder,” Biological Psychiatry, Vol. 40, Issue 12, 1308 – 1310.
  
• Villagomez, et. al., “Iron, Magnesium, Vitamin D, and Zinc Deficiencies in Children Presenting with Symptoms of Attention-Deficit Hyperactivity Disorder,” Children, 2014, 1: 261-279.
  
• Youdim MB, Yehuda S. The neurochemical basis of cognitive deficits induced by brain iron deficiency: involvement of dopamine–opiate system. Cell. Mol. Biol. (Noisy-le-Grand) 46(3), 491–500 (2000).

#10

• Antalis, C.J., et al., “Omega-3 Fatty Acid Status in Attention-Deficit/ Hyperactivity Disorder,” Prostaglandins Leukot Essent Fatty Acids, 2006. 75(4-5): p. 299-308.
  
• Belanger, et. al., “Omega-3 Fatty Acid Treatment of Children with Attention-Deficit Hyperactivity Disorder: A Randomized, Double-Blind, Placebo-Controlled Study,” Pediatric Child Health, 2009; 14(2): p. 89-98.
  
• Bloch, et. al., “Omega-3 Fatty Acid Supplementation for the Treatment of Children with Attention-Deficit/Hyperactivity Disorder Symptomology: Systematic Review and Meta-Analysis,” J Am Acad Child Adolesc Psychiatry, October 2011; 50(10) p. 991-1000.
  
• Bos, et. al., “Reduced Symptoms of Inattention after Dietary Omega-3 Fatty Acid Supplementation in Boys with and without Attention Deficit/Hyperactivity Disorder,” Neuropsychopharmacology, (2015) 40, p. 2298-2306.
  
• Gustafsson, et. al., “EPA Supplementation Improves Teacher-Rated Behavior and Oppositional Symptoms in Children with ADHD.” Acta Paediatr 2010; 99: 1540–1549.
  
• Johnson, et. al., “Omega-3/Omega-6 Fatty Acids for Attention Deficit Disorder: A Randomized Placebo-Controlled Trial in Children and Adolescents,” Journal of Attention Disorders, 2008, p. 1-8.
  
• Konig, et al., “Critical Appraisal of Omega-3 Fatty Acids in Attention-Deficit/Hyperactivity Disorder Treatment,” Neuropsychiatric Disease and Treatment, 2016: 12, p. 1869-1882
  
• Milte, et. al., “Eicosapentaenoic and Docosahexaenoic Acids, Cognition, and Behavior in Children with Attention Deficit/Hyperactivity Disorder: A Randomized Controlled Trial,” Nutrition, (2012) 28; p. 670-677.
  
• Richardson, et. al., “A Randomized Double-Blind, Placebo-Controlled Study of the Effects of Supplementation with Highly Unsaturated Fatty Acids on ADHD-Related Symptoms in Children with Specific Learning Difficulties,” Progress in Neuro-Psychopharmacology Biological Psychiatry, 26 (2002) p. 233-239.
  
• Richardson, et. al., “A Randomized Controlled Trial of Dietary Supplementation with Fatty Acids in Children with Developmental Coordination Disorder,” Pediatrics, 115(5): 1360-1366.
  
• Richardson, et. al., “Omega-3 Fatty Acids in ADHD and Related Neurodevelopmental Disorders,” International Review of Psychiatry, April 2006; 18 (2): p. 155-172.
  
• Richardson, et. al., “The Potential Role of Fatty Acids in Attention-Deficit / Hyperactivity Disorder, “Prostaglandins, Leukotrienes, and Essential Fatty Acids, Vol. 63, Issue 12, July 2000.
  

#11

• Gordon, et al., “Clinically Significant Symptom Reduction in Children with Attention-Deficit/Hyperactivity Disorder Treated with Micronutrients: An Open-Label Reversal Design Study,” J Child Adolesc Psychopharmacol. 2015 Dec 1; 25(10): p. 783–798.
  
• Lakhan, et al. “Nutritional Therapies for Mental Disorders” Nutritional Journal, Jan. 2008; 7:2.
  
• Patrick, et. al., “Vitamin D and the Omega-3 Fatty Acids Control Serotonin Synthesis and Action, part 2: Relevance for ADHD, Bipolar Disorder, Schizophrenia, and Impulsive Behavior,” The FASEB Journal, February 2017, Vol. 29, No. 6, p: 2207-2222.
  
• Saha, et al. “A Pilot Study on the Contribution of Folate Gene Variants in the Cognitive Function of ADHD Probands,” Neurochem Res, (2014) 39: p. 2058-2067.
  
• Sharif, et al., “The Relationship Between Serum Vitamin D Level and Attention-Deficit/Hyperactivity Disorder,” Iranian Journal of Child Neurology, Fall 2015; 9(4): p. 48-53.
  
• Shaw, et al., “A Possible Biological Mechanism for the B Vitamins Altering Behavior in Attention-Deficit/Hyperactivity Disorder,” Pharm Med, 2010; 24 (5): p. 289-294.
  
• Richardson, et. al., “A Randomized Double-Blind, Placebo-Controlled Study of the Effects of Supplementation with Highly Unsaturated Fatty Acids on ADHD-Related Symptoms in Children with Specific Learning Difficulties,” Progress in Neuro-Psychopharmacology Biological Psychiatry, 26 (2002) p. 233-239.
  
• Rucklidge, et. al., “Broad-Spectrum Micronutrient Treatment for Attention-Deficit/Hyperactivity Disorder: Rationale and Evidence to Date,” CNS drugs 28 (2014): 775-785.
  

#12

• Colter, A.L., et. al., “Fatty Acid Status and Behavioral Symptoms of Attention Deficit Hyperactivity Disorder in Adolescents: A Case-Control Study,” Nutr J, 2008. 7: p. 8.
  
• Gow, R.V., et al., “Omega-3 Fatty Acids Are Related to Abnormal Emotion Processing in Adolescent Boys with Attention Deficit Hyperactivity Disorder.” Prostaglandins Leukot Essent Fatty Acids, 2013. 88(6): p. 419-29.
  
• Gow, R.V., et al., “Omega-3 Fatty Acids Are Inversely Related To Callous And Unemotional Traits In Adolescent Boys With Attention Deficit Hyperactivity Disorder,” Prostaglandins Leukot Essent Fatty Acids, 2013. 88(6): p. 411-8.
  
• Richardson, et. al., “Omega-3 Fatty Acids in ADHD and Related Neurodevelopmental Disorders,” International Review of Psychiatry, April 2006; 18 (2): p. 155-172.
  
• Richardson, et. al., “The Potential Role of Fatty Acids in Attention-Deficit / Hyperactivity Disorder, “Prostaglandins, Leukotrienes, and Essential Fatty Acids, Vol. 63, Issue 12, July 2000.
  
• Rucklidge, et. al., “Broad-Spectrum Micronutrient Treatment for Attention-Deficit/Hyperactivity Disorder: Rationale and Evidence to Date,” CNS drugs 28 (2014): 775-785.

#13

• Gordon, et al., “Clinically Significant Symptom Reduction in Children with Attention-Deficit/Hyperactivity Disorder Treated with Micronutrients: An Open-Label Reversal Design Study,” J Child Adolesc Psychopharmacol. 2015 Dec 1; 25(10): p. 783–798.
  
• Lakhan, et al. “Nutritional Therapies for Mental Disorders” Nutritional Journal, Jan. 2008; 7:2.
  
• Patrick, et. al., “Vitamin D and the Omega-3 Fatty Acids Control Serotonin Synthesis and Action, part 2: Relevance for ADHD, Bipolar Disorder, Schizophrenia, and Impulsive Behavior,” The FASEB Journal, February 2017, Vol. 29, No. 6, p: 2207-2222.
  
• Saha, et al. “A Pilot Study on the Contribution of Folate Gene Variants in the Cognitive Function of ADHD Probands,” Neurochem Res, (2014) 39: p. 2058-2067.
  
• Sharif, et al., “The Relationship Between Serum Vitamin D Level and Attention-Deficit/Hyperactivity Disorder,” Iranian Journal of Child Neurology, Fall 2015; 9(4): p. 48-53.
  
• Shaw, et al., “A Possible Biological Mechanism for the B Vitamins Altering Behavior in Attention-Deficit/Hyperactivity Disorder,” Pharm Med, 2010; 24 (5): p. 289-294.
  
• Rucklidge, et. al., “Broad-Spectrum Micronutrient Treatment for Attention-Deficit/Hyperactivity Disorder: Rationale and Evidence to Date,” CNS drugs 28 (2014): 775-785.
  
• Rucklidge, et. al., “Effect of Micronutrients on Behavior and Mood in Adults with ADHD: Evidence From an 8 Week Open Label Trial with Natural Extension,” Journal of Attention Disorders, 15(1) 2011, p. 79-91
  
• Rucklidge, et. al., “Moderators of Treatment Response in Adults with ADHD treated with a Vitamin-Mineral Supplement,” Progress in Neuro-Psychopharmacology & Biological Psychiatry, 50 (2014) p. 163-171.
  
• Rucklidge, et al., “Nutrient Supplementation Approaches in the Treatment of ADHD,” Expert Rev Neurother, 2009; 9(4), p. 461-476.
  
• Rucklidge, et. al., “Vitamin-mineral Treatment of Attention Deficit Hyperactivity Disorder in Adults: Double Blind Randomized Placebo-Controlled Trial,” The British Journal of Psychiatry, (2014) 204, p. 306-315.
  
• Rucklidge, et. al., “Vitamin-mineral Treatment of ADHD in Adults: A 1-Year Naturalistic Follow-Up of a Randomized Controlled Trial,” Journal of Attention Disorders, 2014: p. 1-11.
  

#14

• Colter, A.L., et. al., “Fatty Acid Status and Behavioral Symptoms of Attention Deficit Hyperactivity Disorder in Adolescents: A Case-Control Study,” Nutr J, 2008. 7: p. 8.
  
• Gow, R.V., et al., “Omega-3 Fatty Acids Are Related to Abnormal Emotion Processing in Adolescent Boys with Attention Deficit Hyperactivity Disorder.” Prostaglandins Leukot Essent Fatty Acids, 2013. 88(6): p. 419-29.
  
• Gow, R.V., et al., “Omega-3 Fatty Acids Are Inversely Related To Callous And Unemotional Traits In Adolescent Boys With Attention Deficit Hyperactivity Disorder,” Prostaglandins Leukot Essent Fatty Acids, 2013. 88(6): p. 411-8.
  
• Richardson, et. al., “Omega-3 Fatty Acids in ADHD and Related Neurodevelopmental Disorders,” International Review of Psychiatry, April 2006; 18 (2): p. 155-172.
  
• Richardson, et. al., “The Potential Role of Fatty Acids in Attention-Deficit / Hyperactivity Disorder, “Prostaglandins, Leukotrienes, and Essential Fatty Acids, Vol. 63, Issue 12, July 2000.
  
• Rucklidge, et. al., “Broad-Spectrum Micronutrient Treatment for Attention-Deficit/Hyperactivity Disorder: Rationale and Evidence to Date,” CNS drugs 28 (2014): 775-785
  

#15

• Ghanizadeh, et al., “A systemic Review of Magnesium Therapy for Treating Attention Deficit Hyperactivity Disorder,” Archives of Iranian Medicine, July 2013, 16(7): p. 412-17.
  
• Lakhan, et al. “Nutritional Therapies for Mental Disorders” Nutritional Journal, Jan. 2008; 7:2.
  
• Mousain-Bosc, et al., “Improvement of Neurobehavioral Disorders in Children Supplemented with Magnesium-Vitamin B6 in Attention Deficit Hyperactivity Disorders,” Magnesium Research, 2006; 19(1): p. 46-52.
  
• Rucklidge, et. al., “Broad-Spectrum Micronutrient Treatment for Attention-Deficit/Hyperactivity Disorder: Rationale and Evidence to Date,” CNS drugs 28 (2014): 775-785.
  
• Slutsky, et al., “Enhancement of Learning Memory by Elevating Brain Magnesium,” Nueron, January 2010: 65, p. 165-177.
  
• Toren, et al. “Zinc deficiency in attention-deficit hyperactivity disorder,” Biological Psychiatry, Vol. 40, Issue 12, 1308 – 1310.
  
• Youdim MB, Yehuda S. The neurochemical basis of cognitive deficits induced by brain iron deficiency: involvement of dopamine–opiate system. Cell. Mol. Biol. (Noisy-le-Grand) 46(3), 491–500 (2000).
  

#16

• Amminger, P, et al. "Omega-3 fatty acids supplementation in children with autism: a double-blind randomized, placebo-controlled pilot study." Biological psychiatry 61.4 (2007): 551-553.
  
• Ooi, Y. P., et al. "Omega-3 fatty acids in the management of autism spectrum disorders: findings from an open-label pilot study in Singapore." European journal of clinical nutrition 69.8 (2015): 969-971.
  
• Rucklidge, et. al., “Effect of Micronutrients on Behavior and Mood in Adults with ADHD: Evidence From an 8 Week Open Label Trial with Natural Extension,” Journal of Attention Disorders, 15(1) 2011, p. 79-91
  
• Rucklidge, et. al., “Vitamin-mineral Treatment of Attention Deficit Hyperactivity Disorder in Adults: Double Blind Randomized Placebo-Controlled Trial,” The British Journal of Psychiatry, (2014) 204, p. 306-315.
  
• Richardson, et. al., “Omega-3 Fatty Acids in ADHD and Related Neurodevelopmental Disorders,” International Review of Psychiatry, April 2006; 18 (2): p. 155-172.
  

#17

• Adams, J., et al. "Effect of a vitamin/mineral supplement on children and adults with autism." BMC pediatrics 11 (2011): 1-30.
  
• Abugharsa, Jinan M. "Supplementary Therapy for DNA Methylation in Autism." Egyptian Academic Journal of Biological Sciences. C, Physiology and Molecular Biology 16.1 (2024): 347-354.
  
• Hendren, R., et al. “Randomized, placebo-controlled trial of methyl B12 for children with autism." Journal of child and adolescent psychopharmacology 26.9 (2016): 774-783.
  
• Khan, Farhana, et al. "Vitamin B6 and magnesium on neurobehavioral status of autism spectrum disorder: a randomized, double-blind, placebo controlled study." Bangladesh Journal of Medicine 32.1 (2021): 12-18.
  
• Rucklidge, et. al., “Moderators of Treatment Response in Adults with ADHD treated with a Vitamin-Mineral Supplement,” Progress in Neuro-Psychopharmacology & Biological Psychiatry, 50 (2014) p. 163-171.
  
• Rucklidge, et al., “Nutrient Supplementation Approaches in the Treatment of ADHD,” Expert Rev Neurother, 2009; 9(4), p. 461-476.
  

#18

• Adams, J., et al. "Effect of a vitamin/mineral supplement on children and adults with autism." BMC pediatrics 11 (2011): 1-30.
  
• Colter, A.L., et. al., “Fatty Acid Status and Behavioral Symptoms of Attention Deficit Hyperactivity Disorder in Adolescents: A Case-Control Study,” Nutr J, 2008. 7: p. 8.
  
• Khan, Farhana, et al. "Vitamin B6 and magnesium on neurobehavioral status of autism spectrum disorder: a randomized, double-blind, placebo controlled study." Bangladesh Journal of Medicine 32.1 (2021): 12-18.
  
• Richardson, et. al., “The Potential Role of Fatty Acids in Attention-Deficit / Hyperactivity Disorder, “Prostaglandins, Leukotrienes, and Essential Fatty Acids, Vol. 63, Issue 12, July 2000.
  

#19

• Amminger, P, et al. "Omega-3 fatty acids supplementation in children with autism: a double-blind randomized, placebo-controlled pilot study." Biological psychiatry 61.4 (2007): 551-553.
  
• Antalis, C.J., et al., “Omega-3 Fatty Acid Status in Attention-Deficit/ Hyperactivity Disorder,” Prostaglandins Leukot Essent Fatty Acids, 2006. 75(4-5): p. 299-308.
  
• Ooi, Y. P., et al. "Omega-3 fatty acids in the management of autism spectrum disorders: findings from an open-label pilot study in Singapore." European journal of clinical nutrition 69.8 (2015): 969-971.
  
• Richardson, et. al., “A Randomized Double-Blind, Placebo-Controlled Study of the Effects of Supplementation with Highly Unsaturated Fatty Acids on ADHD-Related Symptoms in Children with Specific Learning Difficulties,” Progress in Neuro-Psychopharmacology Biological Psychiatry, 26 (2002) p. 233-239.
  
• Richardson, et. al., “A Randomized Double-Blind, Placebo-Controlled Study of the Effects of Supplementation with Highly Unsaturated Fatty Acids on ADHD-Related Symptoms in Children with Specific Learning Difficulties,” Progress in Neuro-Psychopharmacology Biological Psychiatry, 26 (2002) p. 233-239.
  
• Rucklidge, et. al., “Broad-Spectrum Micronutrient Treatment for Attention-Deficit/Hyperactivity Disorder: Rationale and Evidence to Date,” CNS drugs 28 (2014): 775-785.

#20

• Abugharsa, J. "Supplementary Therapy for DNA Methylation in Autism." Egyptian Academic Journal of Biological Sciences. C, Physiology and Molecular Biology 16.1 (2024): 347-354.
  
• Hendren, R., et al. “Randomized, placebo-controlled trial of methyl B12 for children with autism." Journal of child and adolescent psychopharmacology 26.9 (2016): 774-783.
  
• Khan, Farhana, et al. "Vitamin B6 and magnesium on neurobehavioral status of autism spectrum disorder: a randomized, double-blind, placebo controlled study." Bangladesh Journal of Medicine 32.1 (2021): 12-18.
  
• Rucklidge, et. al., “Moderators of Treatment Response in Adults with ADHD treated with a Vitamin-Mineral Supplement,” Progress in Neuro-Psychopharmacology & Biological Psychiatry, 50 (2014) p. 163-171.
  
• Rucklidge, et al., “Nutrient Supplementation Approaches in the Treatment of ADHD,” Expert Rev Neurother, 2009; 9(4), p. 461-476.
  

#21

• Deacon, G., et al. "Omega 3 polyunsaturated fatty acids and the treatment of depression." Critical reviews in food science and nutrition 57.1 (2017): 212-223.
  
• Grosso, G., et al. "Role of omega-3 fatty acids in the treatment of depressive disorders: a comprehensive meta-analysis of randomized clinical trials." PloS one 9.5 (2014): e96905.
  
• Hallahan, B., et al. "Efficacy of omega-3 highly unsaturated fatty acids in the treatment of depression." The British Journal of Psychiatry 209.3 (2016): 192-201.
  
• Osher Y., et al. “Omega-3 eicosapentaenoic acid in bipolar depression: Report of a small open-label study.” J Clin Psychiatry 2005; 66: 726–729.
  

#22

• Cicero, A. et al. "Combined action of SAMe, Folate, and Vitamin B12 in the treatment of mood disorders: a review." European review for medical and pharmacological sciences 26.7 (2022): 2443-2459.
  
• Dartois, L., et al. "L-methylfolate augmentation to antidepressants for adolescents with treatment-resistant depression: A case series." Journal of Child and Adolescent Psychopharmacology 29.5 (2019): 386-391.
  
• Jain, R. et al. "Good, better, best: clinical scenarios for the use of L-methylfolate in patients with MDD." CNS spectrums 25.6 (2020): 750-764.
  
• Kose, S. et al. "L-methylfolate in patients with treatment resistant depression: fulfilling the goals of personalized psychopharmacological therapy." Psychiatry and Clinical Psychopharmacology 28.4 (2018): 359-362.
  
• Lewis, J., et al. "The effect of methylated vitamin B complex on depressive and anxiety symptoms and quality of life in adults with depression." International Scholarly Research Notices 2013.1 (2013): 621453.

#23

• Cussotto, S., et al. "Low omega‐3 polyunsaturated fatty acids predict reduced response to standard antidepressants in patients with major depressive disorder." Depression and Anxiety 39.5 (2022): 407-418.
  
• Krawczyk, K. et al. "Augmentation of antidepressants with unsaturated fatty acids omega-3 in drug-resistant depression." Psychiatria polska 46.4 (2012): 585-598.
  
• McNamara, R. et al. "Detection and treatment of long-chain omega-3 fatty acid deficiency in adolescents with SSRI-resistant major depressive disorder." PharmaNutrition 2.2 (2014): 38-46
  

#24

• Cicero, A. et al. "Combined action of SAMe, Folate, and Vitamin B12 in the treatment of mood disorders: a review." European review for medical and pharmacological sciences 26.7 (2022): 2443-2459.
  
• Dartois, L., et al. "L-methylfolate augmentation to antidepressants for adolescents with treatment-resistant depression: A case series." Journal of Child and Adolescent Psychopharmacology 29.5 (2019): 386-391.
  
• Jain, R. et al. "Good, better, best: clinical scenarios for the use of L-methylfolate in patients with MDD." CNS spectrums 25.6 (2020): 750-764.
  
• Kose, S. et al. "L-methylfolate in patients with treatment resistant depression: fulfilling the goals of personalized psychopharmacological therapy." Psychiatry and Clinical Psychopharmacology 28.4 (2018): 359-362.
  

#25

• Bidgoli, M. et al. "Iron: The missing link of depression prevention and treatment." Journal of Biostatistics and Epidemiology 10.1 (2024): 1-18.
  
• da Silva, L., et al. "Zinc supplementation combined with antidepressant drugs for treatment of patients with depression: a systematic review and meta-analysis." Nutrition Reviews 79.1 (2021): 1-12.
  
• Eby, G. et al. "Magnesium for treatment-resistant depression: a review and hypothesis." Medical hypotheses 74.4 (2010): 649-660.
  
• Eby, G. et al. "Rapid recovery from major depression using magnesium treatment." Medical hypotheses 67.2 (2006): 362-370.
  
• Siwek, M., et al. "Zinc supplementation augments efficacy of imipramine in treatment resistant patients: a double blind, placebo-controlled study." Journal of affective disorders 118.1-3 (2009): 187-195.
  
• Tarleton, E, et al. "Role of magnesium supplementation in the treatment of depression: A randomized clinical trial." PloS one 12.6 (2017): e0180067.
  

#26

• Balanzá-Martínez, V, et al. "Therapeutic use of omega-3 fatty acids in bipolar disorder." Expert review of neurotherapeutics 11.7 (2011): 1029-1047.
  
• Montgomery, P. "Omega‐3 fatty acids for bipolar disorder." Cochrane database of systematic reviews 2 (2008).
  
• Osher Y., et al. “Omega-3 eicosapentaenoic acid in bipolar depression: Report of a small open-label study.” J Clin Psychiatry 2005; 66: 726–729.
  
• Patrick, et. al., “Vitamin D and the Omega-3 Fatty Acids Control Serotonin Synthesis and Action, part 2: Relevance for ADHD, Bipolar Disorder, Schizophrenia, and Impulsive Behavior,” The FASEB Journal, February 2017, Vol. 29, No. 6, p: 2207-2222.
  
• Stoll, A., et al. "Omega 3 fatty acids in bipolar disorder: a preliminary double-blind, placebo-controlled trial." Archives of general psychiatry 56.5 (1999): 407-412.
  
• Turnbull, T. et al."Efficacy of omega-3 fatty acid supplementation on improvement of bipolar symptoms: a systematic review." Archives of psychiatric nursing 22.5 (2008): 305-311.
  

#27

• Cicero, A. et al. "Combined action of SAMe, Folate, and Vitamin B12 in the treatment of mood disorders: a review." European review for medical and pharmacological sciences 26.7 (2022): 2443-2459.
  
• Patrick, et. al., “Vitamin D and the Omega-3 Fatty Acids Control Serotonin Synthesis and Action, part 2: Relevance for ADHD, Bipolar Disorder, Schizophrenia, and Impulsive Behavior,” The FASEB Journal, February 2017, Vol. 29, No. 6, p: 2207-2222.
  

#28

• Ashton, M. et al. "A systematic review of nutraceuticals for the treatment of bipolar disorder." The Canadian Journal of Psychiatry 66.3 (2021): 262-273.
  
• Balanzá-Martínez, V, et al. "Therapeutic use of omega-3 fatty acids in bipolar disorder." Expert review of neurotherapeutics 11.7 (2011): 1029-1047.
  
• Montgomery, P. "Omega‐3 fatty acids for bipolar disorder." Cochrane database of systematic reviews 2 (2008).
  
• Patrick, et. al., “Vitamin D and the Omega-3 Fatty Acids Control Serotonin Synthesis and Action, part 2: Relevance for ADHD, Bipolar Disorder, Schizophrenia, and Impulsive Behavior,” The FASEB Journal, February 2017, Vol. 29, No. 6, p: 2207-2222.
  
• Stoll, A., et al. "Omega 3 fatty acids in bipolar disorder: a preliminary double-blind, placebo-controlled trial." Archives of general psychiatry 56.5 (1999): 407-412.
  
• Sylvia, Louisa G., et al. "Nutrient-based therapies for bipolar disorder: a systematic review." Psychotherapy and psychosomatics 82.1 (2012): 10-19.
  
• Turnbull, T. et al."Efficacy of omega-3 fatty acid supplementation on improvement of bipolar symptoms: a systematic review." Archives of psychiatric nursing 22.5 (2008): 305-311.
  

#29

• Rakofsky, J. et al. "Review of nutritional supplements for the treatment of bipolar depression." Depression and anxiety 31.5 (2014): 379-390.
  
• Sylvia, Louisa G., et al. "Nutrient-based therapies for bipolar disorder: a systematic review." Psychotherapy and psychosomatics 82.1 (2012): 10-19.

#30

• Kiecolt-Glaser, J. et al. "Omega-3 supplementation lowers inflammation and anxiety in medical students: a randomized controlled trial." Brain, behavior, and immunity 25.8 (2011): 1725-1734.
  
• Larrieu, T. "Food for mood: relevance of nutritional omega-3 fatty acids for depression and anxiety." Frontiers in physiology 9 (2018): 1047.
  
• Polokowski, A. et al. "Omega-3 fatty acids and anxiety: A systematic review of the possible mechanisms at play." Nutritional neuroscience 23.7 (2020): 494-504.
  
• Ross, B,. "Omega-3 polyunsaturated fatty acids and anxiety disorders." Prostaglandins, Leukotrienes and Essential Fatty Acids 81.5-6 (2009): 309-312.
  
• Su, K., et al. "Association of use of omega-3 polyunsaturated fatty acids with changes in severity of anxiety symptoms: a systematic review and meta-analysis." JAMA network open 1.5 (2018): e182327-e182327.
  
• Thesing, C. , et al. "Omega-3 and omega-6 fatty acid levels in depressive and anxiety disorders." Psychoneuroendocrinology 87 (2018): 53-62.
  

#31

• Borges-Vieira, J. et al. "Efficacy of B-vitamins and vitamin D therapy in improving depressive and anxiety disorders: a systematic review of randomized controlled trials." Nutritional neuroscience 26.3 (2023): 187-207.
  
• Lewis, J., et al. "The effect of methylated vitamin B complex on depressive and anxiety symptoms and quality of life in adults with depression." International Scholarly Research Notices 2013.1 (2013): 621453.
  
• Young, L. , et al. "A systematic review and meta-analysis of B vitamin supplementation on depressive symptoms, anxiety, and stress: Effects on healthy and ‘at-risk’individuals." Nutrients 11.9 (2019): 2232.
  

#32

• Coletta, J. et al. "Omega-3 fatty acids and pregnancy." Reviews in obstetrics and gynecology 3.4 (2010): 163.
  
• Greenberg, J. et al. "Omega-3 fatty acid supplementation during pregnancy." Reviews in obstetrics and Gynecology 1.4 (2008): 162.
• Hermans, E., et al. "Dietary LPC-Bound n-3 LCPUFA Protects against Neonatal Brain Injury in Mice but Does Not Enhance Stem Cell Therapy." Nutrients 16.14 (2024): 2252.
  

#33

• McGarel, C., et al. "Emerging roles for folate and related B-vitamins in brain health across the lifecycle." Proceedings of the Nutrition Society 74.1 (2015): 46-55.
  
• Molloy, A. et al. "Effects of folate and vitamin B12 deficiencies during pregnancy on fetal, infant, and child development." Food and nutrition bulletin 29.2_suppl1 (2008): S101-S111.
  
• Moore, C., et al. "Diet in early pregnancy: focus on folate, vitamin B12, vitamin D, and choline." Canadian Journal of Dietetic Practice and Research 81.2 (2019): 58-65.
  

#34

• Bothwell, T. et al. "Iron requirements in pregnancy and strategies to meet them." The American journal of clinical nutrition 72.1 (2000): 257S-264S.
  
• Georgieff, M. et al."Iron deficiency in pregnancy." American journal of obstetrics and gynecology 223.4 (2020): 516-524.
  
• Hovdenak, N. et al. "Influence of mineral and vitamin supplements on pregnancy outcome." European Journal of Obstetrics & Gynecology and Reproductive Biology 164.2 (2012): 127-132.
  
• Scholl, T. et al. "Anemia, iron and pregnancy outcome." The Journal of nutrition 130.2 (2000): 443S-447S.
  

#35

• Dacks, P. et al. "Current evidence for the clinical use of long-chain polyunsaturated n-3 fatty acids to prevent age-related cognitive decline and Alzheimer's disease." The Journal of nutrition, health and aging 17.3 (2013): 240-251.
  
• Martí, A. et al. "Omega-3 fatty acids and cognitive decline: a systematic review." Nutr. Hosp 36 (2019): 939-949.
  
• Oulhaj, A. et al. "Omega-3 fatty acid status enhances the prevention of cognitive decline by B vitamins in mild cognitive impairment." Journal of Alzheimer's Disease 50.2 (2016): 547-557.
  
• Soderberg, M., et al., Lipid composition in different regions of the brain in Alzheimer's disease/senile dementia of Alzheimer's type. J Neurochem, 1992. 59(5): p. 1646-53.
  
• Wood, A. et al. "Dietary and supplemental long-chain omega-3 fatty acids as moderators of cognitive impairment and Alzheimer’s disease." European journal of nutrition (2022): 1-16.
  

#36

#37

#38

• Emsley, R. et al. "Clinical potential of omega-3 fatty acids in the treatment of schizophrenia." CNS drugs 17 (2003): 1081-1091.
  
• Hsu, M. et al, "Beneficial effects of omega-3 fatty acid supplementation in schizophrenia: possible mechanisms." Lipids in health and disease 19 (2020): 1-17.
  
• Pawełczyk, T. et al. "A randomized controlled study of the efficacy of six-month supplementation with concentrated fish oil rich in omega-3 polyunsaturated fatty acids in first episode schizophrenia." Journal of Psychiatric Research 73 (2016): 34-44.
  
• Pawełczyk, T., et al. "Omega-3 fatty acids in first-episode schizophrenia-a randomized controlled study of efficacy and relapse prevention (OFFER): rationale, design, and methods." BMC psychiatry 15 (2015): 1-13.
  
• Peet, M., et al. "Omega-3 fatty acids in the treatment of psychiatric disorders." Drugs 65 (2005): 1051-1059.
  

#39

• Susai, S. et al. "Omega‐3 fatty acid in ultra‐high‐risk psychosis: A systematic review based on functional outcome." Early intervention in psychiatry 16.1 (2022): 3-16.

#40

• Barrett, E. et al. "ω-3 fatty acid supplementation as a potential therapeutic aid for the recovery from mild traumatic brain injury/concussion." Advances in nutrition 5.3 (2014): 268-277.
  
• Heileson, J. , et al. "The effect of omega-3 fatty acids on a biomarker of head trauma in NCAA football athletes: a multi-site, non-randomized study." Journal of the International Society of Sports Nutrition 18 (2021): 1-13.
  
• Lewis, M. "Concussions, traumatic brain injury, and the innovative use of omega-3s." Journal of the American College of Nutrition 35.5 (2016): 469-475.
  
• Patch, S., et al. "The more, the better: high-dose omega-3 fatty acids improve behavioural and molecular outcomes in preclinical models in mild brain injury." Current Neurology and Neuroscience Reports 21 (2021): 1-14.
  

#41

• Cardia, L., et al. "Clinical use of omega-3 fatty acids in migraine: a narrative review." Medicine 99.42 (2020): e22253.
  
• Harel, Z., et al. "Supplementation with omega-3 polyunsaturated fatty acids in the management of recurrent migraines in adolescents." Journal of Adolescent Health 31.2 (2002): 154-161.
  
• Maghsoumi-Norouzabad, L., et al. "Effects of omega-3 fatty acids on the frequency, severity, and duration of migraine attacks: A systematic review and meta-analysis of randomized controlled trials." Nutritional Neuroscience 21.9 (2018): 614-623.
  
• Soares, A., et al. "A double-blind, randomized, and placebo-controlled clinical trial with omega-3 polyunsaturated fatty acids (OPFA ɷ-3) for the prevention of migraine in chronic migraine patients using amitriptyline." Nutritional Neuroscience 21.3 (2018): 219-223.
  
• Soveyd, N., et al. "Molecular mechanisms of omega-3 fatty acids in the migraine headache." Iranian journal of neurology 16.4 (2017): 210.
  

#42

• Cardia, L., et al. "Clinical use of omega-3 fatty acids in migraine: a narrative review." Medicine 99.42 (2020): e22253.
  
• Harel, Z., et al. "Supplementation with omega-3 polyunsaturated fatty acids in the management of recurrent migraines in adolescents." Journal of Adolescent Health 31.2 (2002): 154-161.
  
• Maghsoumi-Norouzabad, L., et al. "Effects of omega-3 fatty acids on the frequency, severity, and duration of migraine attacks: A systematic review and meta-analysis of randomized controlled trials." Nutritional Neuroscience 21.9 (2018): 614-623.
  
• Soares, A., et al. "A double-blind, randomized, and placebo-controlled clinical trial with omega-3 polyunsaturated fatty acids (OPFA ɷ-3) for the prevention of migraine in chronic migraine patients using amitriptyline." Nutritional Neuroscience 21.3 (2018): 219-223.
  
• Soveyd, N., et al. "Molecular mechanisms of omega-3 fatty acids in the migraine headache." Iranian journal of neurology 16.4 (2017): 210.
  

#43

• Sanders, et. al., "Long-chain omega-3 fatty acids and headache in the US population." Prostaglandins, Leukotrienes and Essential Fatty Acids 135 (2018): 47-53.

#44

• Sanders, et. al., "Long-chain omega-3 fatty acids and headache in the US population." Prostaglandins, Leukotrienes and Essential Fatty Acids 135 (2018): 47-53.

#45

#46

#47

#48

#49

#50